Analysis of Relationship between Levofloxacin and Corrected QT Prolongation Using a Clinical Data Warehouse

Objective The aim of this study was to examine whether or not levofloxacin has any relationship with QT prolongation in a real clinical setting by analyzing a clinical data warehouse of data collected from different hospital information systems. Methods Electronic prescription data and medical charts from 3 different hospitals spanning the past 9 years were reviewed, and a clinical data warehouse was constructed. Patients who were both administrated levofloxacin and given electrocardiograms (ECG) were selected. The correlations between various patient characteristics, concomitant drugs, corrected QT (QTc) prolongation, and the interval difference in QTc before and after levofloxacin administration were analyzed. Results A total of 2,176 patients from 3 different hospitals were included in the study. QTc prolongation was found in 364 patients (16.7%). The study revealed that age (OR 1.026, p < 0.001), gender (OR 0.676, p = 0.007), body temperature (OR 1.267, p = 0.024), and cigarette smoking (OR 1.641, p = 0.022) were related with QTc prolongation. After adjusting for related factors, 12 drugs concomitant with levofloxacin were associated with QTc prolongation. For patients who took ECGs before and after administration of levofloxacin during their hospitalization (n = 112), there was no significant difference in QTc prolongation. Conclusions The age, gender, body temperature, cigarette smoking and various concomitant drugs might be related with QTc prolongation. However, there was no definite causal relationship or interaction between levofloxacin and QTc prolongation. Alternative surveillance methods utilizing the massive accumulation of electronic medical data seem to be essential to adverse drug reaction surveillance in future.

[1]  A. Camm,et al.  Levofloxacin can be used effectively as a positive control in thorough QT/QTc studies in healthy volunteers. , 2010, British journal of clinical pharmacology.

[2]  Rae Woong Park,et al.  A Data Warehouse Based Retrospective Post-marketing Surveillance Method: A Feasibility Test with Fluoxetine , 2009 .

[3]  Sowmya R. Rao,et al.  Electronic health records in ambulatory care--a national survey of physicians. , 2008, The New England journal of medicine.

[4]  S. Sheen,et al.  Overdose Rate of Drugs Requiring Renal Dose Adjustment: Data Analysis of 4 Years Prescriptions at a Tertiary Teaching Hospital , 2008, Journal of General Internal Medicine.

[5]  Nicolae B. Szirbik,et al.  Six methodological steps to build medical data warehouses for research , 2006, Int. J. Medical Informatics.

[6]  Sachin Agarwal,et al.  Heparin-induced transient prolongation of the QT interval during endovascular embolisation of intracranial aneurysm , 2006, Journal of Clinical Neuroscience.

[7]  Michael J. Peeters,et al.  Effects of Three Fluoroquinolones on QT Analysis After Standard Treatment Courses , 2006, Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc.

[8]  Jocelyn G Dewitt,et al.  Development of a Data Warehouse at an Academic Health System: Knowing a Place for the First Time , 2005, Academic medicine : journal of the Association of American Medical Colleges.

[9]  Rae Woong Park,et al.  Research Paper: Computerized Physician Order Entry and Electronic Medical Record Systems in Korean Teaching and General Hospitals: Results of a 2004 Survey , 2005, J. Am. Medical Informatics Assoc..

[10]  D. Nykamp,et al.  QTc Prolongation Associated with Combination Therapy of Levofloxacin, Imipramine, and Fluoxetine , 2005, The Annals of pharmacotherapy.

[11]  K. Singh Effect of smoking on QT interval, QT dispersion and rate pressure product. , 2004, Indian heart journal.

[12]  K. Hiratsuka,et al.  Comparative assessment of prurifloxacin, sparfloxacin, gatifloxacin and levofloxacin in the rabbit model of proarrhythmia. , 2004, The Journal of toxicological sciences.

[13]  K. Ramaswamy,et al.  Fluconazole- and levofloxacin-induced torsades de pointes in an intensive care unit patient. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[14]  A. Camm,et al.  Drug induced QT prolongation and torsades de pointes , 2003, Heart.

[15]  B. Fermini,et al.  The impact of drug-induced QT interval prolongation on drug discovery and development , 2003, Nature Reviews Drug Discovery.

[16]  William J Brady,et al.  Electrocardiographic manifestations of hypothermia. , 2002, The American journal of emergency medicine.

[17]  R. Bonnel,et al.  GI events leading to death in association with celecoxib and rofecoxib* , 2001, American Journal of Gastroenterology.

[18]  S. Viskin Long QT syndromes and torsade de pointes , 1999, The Lancet.

[19]  A. Camm,et al.  The current cardiac safety situation with antihistamines , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[20]  T. Kakuta,et al.  Increased QT dispersion in patients with vasospastic angina. , 1998, Circulation.

[21]  A. Moss,et al.  The Long QT Syndrome: Prospective Longitudinal Study of 328 Families , 1991, Circulation.

[22]  H C Bazett,et al.  The time relations of the blood‐pressure changes after excision of the adrenal glands, with some observations on blood volume changes , 1920, The Journal of physiology.

[23]  Mph Dr. Syed Rizwanuddin Ahmad MD Adverse drug event monitoring at the food and drug administration , 2007, Journal of General Internal Medicine.

[24]  Y Matsumura,et al.  The Application of an Institutional Clinical Data Warehouse to the Assessment of Adverse Drug Reactions (ADRs) , 2007, Methods of Information in Medicine.

[25]  T. Lieu,et al.  Application of Information Technology: Using Electronic Medical Records to Enhance Detection and Reporting of Vaccine Adverse Events , 2007, J. Am. Medical Informatics Assoc..

[26]  Vaishali K. Patadia,et al.  Data mining in pharmacovigilance: the need for a balanced perspective. , 2005, Drug safety.

[27]  Vaishali K. Patadia,et al.  Data Mining in Pharmacovigilance , 2005 .

[28]  A. Browna Drugs , hERG and sudden death , 2004 .

[29]  Patrick C Waller,et al.  A model for the future conduct of pharmacovigilance , 2003, Pharmacoepidemiology and drug safety.

[30]  R. Woosley,et al.  Cardiac actions of antihistamines. , 1996, Annual review of pharmacology and toxicology.